L01AX03 · Antineoplastic and immunomodulating agents
Temozolomide Accord
Indications
For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Composition
- Active substance
- temozolomide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Temozolomide Accord
- Active substance
- temozolomide
- ATC code
- L01AX03
- Therapeutic area
- Glioma